Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat ...

Guselkumab significantly improves clinical remission rates in patients with active ulcerative colitis, according to phase 3 data.

WASHINGTON -- Induction and maintenance treatment with guselkumab (Tremfya) demonstrated its safety and efficacy for patients with moderately to severely active Crohn's disease, topping both ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

The expansion aims to help address the global shortfall of nu Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

Guselkumab, an IL-23 inhibitor, is effective in reducing signs, symptoms, and structural damage in active PsA, as confirmed by the APEX study. The FDA approved guselkumab in 2020 based on DISCOVER ...

A new study found that 57.6% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin clearance at week 20. Bio-naive status and lower comorbidity ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis ...

May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to ...